A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Atavistik Bio, Inc
K36 Therapeutics, Inc.
Blue Earth Therapeutics Ltd
Eli Lilly and Company
Pathos AI, Inc.
Marengo Therapeutics, Inc.
Lipac Oncology LLC
Eli Lilly and Company
Advanced Accelerator Applications
Endocyte
Novartis
UroGen Pharma Ltd.
Poseida Therapeutics, Inc.
Promontory Therapeutics Inc.
Aragon Pharmaceuticals, Inc.
NanOlogy, LLC
NanOlogy, LLC
Advanced Accelerator Applications
Celldex Therapeutics
LEO Pharma
NanOlogy, LLC
Celldex Therapeutics
Celldex Therapeutics
Endo Pharmaceuticals
Novartis
Dendreon
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Life Molecular Imaging SA
Pfizer
Pierre Fabre Medicament
UroGen Pharma Ltd.
Arno Therapeutics
Medical Enterprises Europe B.V.
Merck Sharp & Dohme LLC
Tesaro, Inc.
Pfizer
Pharmacyclics LLC.